1IJ Stock Chart & Stats
€6.55
--
Market closed
€6.55
--
Day’s Range― - ―
52-Week Range€5.05 - €15.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.00
Market Cap
€73.61M
Enterprise Value€53.37M
Total Cash (Recent Filing)€137.59M
Total Debt (Recent Filing)€13.90M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 06, 2026EPS Estimate
-1.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.90
Shares Outstanding9,348,236
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€17.94Price Target Upside173.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-7.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Allogeneic Γδ T‑cell Therapy PlatformAdicet's focus on off‑the‑shelf γδ T‑cell therapies represents a durable platform strategy: a scalable, potentially broadly applicable product approach across hematologic and solid tumors. Platform assets can drive multi‑indication pipelines and partnership/licensing opportunities over time.
Low Leverage On Balance SheetVery modest debt relative to equity reduces near‑term default risk and interest burden, giving management financial flexibility to prioritize R&D and clinical development. Lower leverage supports resilience during additional capital raises or prolonged clinical timelines.
Institutional Investor Engagement (RA Capital)The RA Capital exchange signals committed institutional support and structured equity flexibility. Such strategic investor arrangements can provide longer‑term financing optionality, voting alignment and potential follow‑on participation, which bolsters funding credibility for development programs.
Bears Say
No Product Revenue; Sustained Net LossesThe absence of product revenue and large recurring operating losses means Adicet cannot self‑fund growth. Persistent losses require ongoing external capital, limit reinvestment from operations, and mean commercial viability hinges on clinical successes that remain uncertain over the medium term.
High Cash Burn And Weak Cash GenerationSustained ~‑$90M annual cash outflow is structurally significant for a clinical‑stage biotech: it shortens runway absent new financing, increases dilution risk from equity raises, and forces prioritization of programs, potentially delaying or truncating development plans.
Eroding Equity Base From Accumulated LossesA materially reduced equity base reflects cumulative losses and shrinking financial cushion. This deterioration increases reliance on external funding, raises governance and solvency risk over time, and heightens the potential for dilutive financings if clinical progress stalls.
Adicet Bio News
1IJ FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest stock price was €5.05 and its highest was €15.00 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is €73.61M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 30 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on May 13, 2026. The company reported -€1.642 earnings per share for the quarter, beating the consensus estimate of -€2.687 by €1.045.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc does not currently pay dividends.
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -1.75.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,348,236 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -€1.642 in its last earnings report, beating expectations of -€2.687. Following the earnings report the stock price went up 2.326%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in DE:1IJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€17.94 (173.83% Upside)
€17.94 (173.83% Upside)
Blogger Sentiment
Bullish
DE:1IJ Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth €816.2K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.38%
12-Months-Change
Fundamentals
Return on Equity
-80.35%
Trailing 12-Months
Asset Growth
-11.44%
Trailing 12-Months
Company Description
Adicet Bio Inc
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.
1IJ Stock 12 Month Forecast
Average Price Target
€17.94
▲(173.83% Upside)
Options Prices
Currently, No data available
---